A PROVEN
FIRST-LINE
TREATMENT OPTION
FOR HEMOPHILIA A

In the clinical study of 19 patients, 82% of bleeding episodes (n=306) were treated successfully with a single KOĀTE infusion.1*

* Dose and duration of treatment depend on the severity of the FVIII deficiency, location and extent of bleeding, and the patient's clinical condition.

In the clinical study, no evidence of inhibitor formation was observed in 34 previously treated patients over the course of 6 months treatment.2✝

The median number of exposure days in the study was more than 50 days (range of 2394).

The formation of inhibitors to KOĀTE may occur. Monitor all patients for the development of FVIII inhibitors by clinical observation and laboratory tests.1

References: 1. KOĀTE [prescribing information]. Fort Lee, NJ. Kedrion Biopharma Inc. 2018. 2. Powell JS, Bush M, Harrison J, et al. Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A. Haemophilia. 2000;6:140-149.

Back to top